The FDA designates Sun BioPharma’s (OTCQB:SNBP) lead candidate SBP-101 for Fast Track review for the treatment of patients with pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.
Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial in these patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.